ReviewJournal of the American Society of Nephrology : JASN2017
The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications.
Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 92 citations in OpenAlex.
- Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?Medical sciences (Basel, Switzerland) · 2026Review
- Autoreactive antibody production by intrarenal B cells in mouse kidney allograft rejection.bioRxiv : the preprint server for biology · 2026Article
- Human antibody repertoire among kidney donors with and without HIV.JCI insight · 2026Article
- Update on diagnostic and therapeutic strategies for antibody-mediated rejection in kidney transplantation.World journal of transplantation · 2026Review
- Impact of ischemia duration on MRI-derived perfusion parameters in a mouse kidney transplant model.European radiology experimental · 2026Article
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.Frontiers in immunology · 2026Review
- The risk of kidney transplant graft loss in sensitized vs. unsensitized patients is modified by prior transplant status.Frontiers in transplantation · 2026Article
- Understanding the role of non-HLA antibodies in kidney transplantation: a literature review.Frontiers in immunology · 2026Review
- Non-human leukocyte antigen antibodies in kidney transplantation: pathogenic mechanisms, detection methods, and clinical implications.Clinical transplantation and research · 2025Review
- Inhibition of De Novo Autoantibody Production Attenuates Chronic Antibody-Mediated Rejection of Kidney Allografts Despite Maintenance of High Donor-Specific Antibody Titers.bioRxiv : the preprint server for biology · 2025Article
- From Banff 1991 to Today: The Changing Landscape of the v-Lesion in Kidney Transplant Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Comprehensive Characterization of Anti-HLA and Non-HLA Antibodies in Patients on Kidney Transplant Waiting List and Evaluation of Their Impact on Alloimmunization Risk and Dialysis Treatment.International journal of molecular sciences · 2024Article
- Angiotensin II Type-1 Receptor Antibody in Solid Organ Transplantation - Is It Time to Test?Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Re-Evaluating the Transplant Glomerulopathy Lesion-Beyond Donor-Specific Antibodies.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Autoantibodies against DNA topoisomerase I promote renal allograft rejection by increasing alloreactive T cell responses.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Association between anti-endothelial antigen antibodies and allograft rejection in kidney transplantation.Journal of clinical laboratory analysis · 2023Article
- Glomerulonephritis: immunopathogenesis and immunotherapy.Nature reviews. Immunology · 2023Review
- Establishment of Reference Values for Non-HLA Antibodies in Patients With End-stage Renal Disease.Annals of laboratory medicine · 2023Article
- The role of lung-restricted autoantibodies in the development of primary and chronic graft dysfunction.Frontiers in transplantation · 2023Review
- Immune surveillance and humoral immune responses in kidney transplantation - A look back at T follicular helper cells.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies that are specific to organ donor HLA have been involved in the majority of cases of antibody-mediated rejection in solid organ transplant recipients. However, recent data show that production of non-HLA autoantibodies can occur before transplant in the form of natural autoantibodies. In contrast to HLAs, which are constitutively expressed on the cell surface of the allograft endothelium, autoantigens are usually cryptic. Tissue damage associated with ischemia-reperfusion, vascular injury, and/or rejection creates permissive conditions for the expression of cryptic autoantigens, allowing these autoantibodies to bind antigenic targets and further enhance vascular inflammation and renal dysfunction. Antiperlecan/LG3 antibodies and antiangiotensin II type 1 receptor antibodies have been found before transplant in patients with de novo transplants and portend negative long-term outcome in patients with renal transplants. Here, we review mounting evidence suggesting an important role for autoantibodies to cryptic antigens as novel accelerators of kidney dysfunction and acute or chronic allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.